Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 11, 2006, Pages 1143-1150

  Senzolo, Marco ^a   Cholongitas, Evangelos ^a   Tibballs, Jonathan ^a   Burroughs, Andrew ^a   Patch, David ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Ascites; Cirrhosis; Hepatorenal syndrome; Portal hypertension; Transjugular intrahepatic shunt

Indexed keywords

ALBUMIN; DIURETIC AGENT; VASOCONSTRICTOR AGENT;

ASCITES; BRAIN DISEASE; COST UTILITY ANALYSIS; DISEASE SEVERITY; EVALUATION; HEPATORENAL SYNDROME; HOSPITAL ADMISSION; HUMAN; LIVER TRANSPLANTATION; MORTALITY; OUTCOME ASSESSMENT; PARACENTESIS; PATHOGENESIS; PATIENT SELECTION; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION;

ASCITES; COHORT STUDIES; COSTS AND COST ANALYSIS; HEPATORENAL SYNDROME; HUMANS; HYPERTENSION, PORTAL; KIDNEY; NATRIURESIS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; TREATMENT OUTCOME;

EID: 33749829702     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.meg.0000236872.85903.3f     Document Type: Review

References (53)

1. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350:1646-1654.
2. Russo MW, Sood A, Jacobson IM, Brown RS Jr. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Am J Gastroenterol 2003; 98:2521-2527.
3. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8:1151-1157.
4. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339:533-541.
5. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38 (Suppl 1):S69-S89.
6. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the international ascites club. Hepatology 2003; 38:258-266.
7. Cardenas A, Uriz J, Gines P, Arroyo V. Hepatorenal syndrome. Liver Transpl 2000; 6 (4 Suppl 1):S63-S71.
8. Morali GA, Sniderman KW, Deitel KM, Tobe S, Witt-Sullivan H, Simon M, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 1992; 16:249-250.
9. Rector WG Jr. Portal hypertension: a permissive factor only in the development of ascites and variceal bleeding. Liver 1986; 6:221-226.
10. Orloff MJ, Orloff MS, Orloff SL, Girard B. Experimental, clinical, and metabolic results of side-to-side portacaval shunt for intractable cirrhotic ascites. J Am Coll Surg 1997; 184:557-570.
11. Franco D, Vons C, Traynor O, de Smadja C. Should portosystemic shunt be reconsidered in the treatment of intractable ascites in cirrhosis? Arch Surg 1988; 123:987-991.
12. Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient: preliminary report of a prospective study. Hepatology 1994; 19:129-132.
13. Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, Garcia-Villarreal L, et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 1995; 21:986-994.
14. Martinet JP, Fenyves D, Legault L, Roy L, Dufresne MP, Spahr L, et al. Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution. Dig Dis Sci 1997; 42:161-166.
15. Gerbes AL, Gulberg V, Waggershauser T, Holl J, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 1998; 28:683-688.
16. Wong F, Blendis L. Transjugular intrahepatic portosystemic shunt for refractory ascites: tipping the sodium balance. Hepatology 1995; 22:358-364.
17. Wong F, Sniderman K, Liu P, Blendis L. The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology 1997; 112:899-907.
18. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 1995; 122:816-822.
19. Lang F, Tschernko E, Schulze E, Ottl I, Ritter M, Volkl H, et al. Hepatorenal reflex regulating kidney function. Hepatology 1991; 14 (4 Pt 1):590-594.
20. Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997; 40:664-670.
21. Wensing G, Lotterer E, Link I, Hahn EG, Fleig WE. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function. Hepatology 1997; 26:1149-1155.
22. Jalan R, Hayes PC. Sodium handling in patients with well compensated cirrhosis is dependent on the severity of liver disease and portal pressure. Gut 2000; 46:527-533.
23. Thuluvath PJ, Bal JS, Mitchell S, Lund G, Venbrux A. TIPS for management of refractory ascites: response and survival are both unpredictable. Dig Dis Sci 2003; 48:542-550.
24. Alessandria C, Gaia S, Marzano A, Venon WD, Fadda M, Rizzetto M. Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment. Eur J Gastroenterol Hepatol 2004; 16:607-612.
25. Forrest EH, Stanley AJ, Redhead DN, McGilchrist AJ, Hayes PC. Clinical response after transjugular intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis. Aliment Pharmacol Ther 1996; 10:801-806.
26. Rees CJ, Rose JD, Record CO, Day CP, Bassendine MF, James OF, et al. Transjugular intrahepatic portosystemic shunt: a limited role in refractory ascites. Eur J Gastroenterol Hepatol 1997; 9:969-973.
27. Trotter JF, Suhocki PV, Rockey DC. Transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites: effect on body weight and Child-Pugh score. Am J Gastroenterol 1998; 93:1891-1894.
28. Williams DB, Waugh R, Selby W. Transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of refractory ascites. Aust N Z J Med 1998; 28:620-626.
29. Crenshaw WB, Gordon FD, McEniff NJ, Perry LJ, Hartnell G, Anastopoulos H, et al. Severe ascites: efficacy of the transjugular intrahepatic portosystemic shunt in treatment. Radiology 1996; 200:185-192.
30. Deschenes M, Dufresne MP, Bui B, Fenyves D, Spahr L, Roy L, et al. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites. Am J Gastroenterol 1999; 94:1361-1365.
31. Nazarian GK, Bjarnason H, Dietz CA Jr, Bernadas CA, Foshager MC, Ferral H, et al. Refractory ascites: midterm results of treatment with a transjugular intrahepatic portosystemic shunt. Radiology 1997; 205:173-180.
32. Ochs A, Rossle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995; 332:1192-1197.
33. Somberg KA, Lake JR, Tomlanovich SJ, LaBerge JM, Feldstein V, Bass NM. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 1995; 21:709-716.
34. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123:1839-1847.
35. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French group of clinicians and a group of biologists. J Hepatol 1996; 25:135-144.
36. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342:1701-1707.
37. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40:629-635.
38. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al. The North American study for the treatment of refractory ascites. Gastroenterology 2003; 124:634-641.
39. Nair S, Singh R, Yoselewitz M. Correlation between portal/hepatic vein gradient and response to transjugular intrahepatic portosystemic shunt creation in refractory ascites. J Vasc Interv Radiol 2004; 15:1431-1434.
40. Campbell MS, Brensinger CM, Sanyal AJ, Gennings C, Wong F, Kowdley KV, et al. Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology 2005; 42:635-640.
41. Gulberg V, Liss I, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts. Digestion 2002; 66:127-130.
42. Allard JP, Chau J, Sandokji K, Blendis LM, Wong F. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am J Gastroenterol 2001; 96:2442-2447.
43. Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126:469-475.
44. Arroyo V. Review article: hepatorenal syndrome-how to assess response to treatment and nonpharmacological therapy. Aliment Pharmacol Ther 2004; 20 (Suppl 3):49-54.
45. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003; 362:1819-1827.
46. Schroeder ET, Anderson GH Jr, Smulyan H. Effects of a portacaval or peritoneovenous shunt on renin in the hepatorenal syndrome. Kidney Int 1979; 15:54-61.
47. Schroeder ET, Numann PJ, Chamberlain BE. Functional renal failure in cirrhosis. Recovery after portacaval shunt. Ann Intern Med 1970; 72:923-928.
48. Ariyan S, Sweeney T, Kerstein MD. The hepatorenal syndrome: recovery after portacaval shunt. Ann Surg 1975; 181:847-849.
49. Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28:416-422.
50. Brensing KA, Textor J, Strunk H, Klehr HU, Schild H, Sauerbruch T. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997; 349:697-698.
51. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47:288-295.
52. Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B, et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 2003; 50:1753-1755.
53. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40:55-64.